tirzepatide cardiovascular outcomes trial 2024 American Heart Association Scientific Sessions has started off with a bang! Results are in for the SUMMIT study: Treatment with (Mounjaro/ Zepbound) was associated with 38% ⬇️ in combined risk Will tirzepatide or semaglutide prove
Description
[Google Scholar] [24].Cerillo JL, and Parmar M
American Diabetes Association
The recent approval of tirzepatide, the first dual glucose dependent insulinotropic polypeptide and GLP 1 receptor agonist, challenges the long held assumption that targeting a single hormonal pathway is sufficient for optimal metabolic control
The escalation schedule is not rigid
Do not try to compensate
This dual mechanism is why the SURPASS and SURMOUNT clinical trials showed unprecedented results
